生物技术与制药领域的最新动态
Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing - Yahoo Finance
Looking At Agilent Technologies's Recent Unusual Options Activity - Benzinga
Retraction notice to: Transcriptome-scale RNA-targeting CRISPR screens reveal essential lncRNAs in human cells
Fertilization triggers early proteomic symmetry breaking in mammalian embryos
After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg
Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific
Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision
After more than 20 years, Medtronic claims deep brain stimulation approval for dystonia
A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes
Thermo Fisher Scientific (TMO): Reassessing Valuation After Recent Share Price Gains - simplywall.st
Transcript : Agilent Technologies, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09 - MarketScreener
Global insights on scaling and integrating digital health - Roche
UniQure restates FDA's negative feedback on Huntington's trial; Neurimmune's expanded AstraZeneca alliance
BioNexus gets $500M to step into manufacturing; Thermo Fisher, AtomVie expand
BioNexus gets $500M to step into manufacturing; Thermo Fisher, AtomVie expand - Endpoints News
Facts getting lost in ACIP hep B discussion?
UniQure slides further on outlook for Huntington’s gene therapy
What Made Thermo Fisher Scientific (TMO) a Solid Performer in Q3? - Insider Monkey
What Made Thermo Fisher Scientific (TMO) a Solid Performer in Q3? - Yahoo Finance
Crescent forms PD-1xVEGF, ADC pact with Kelun, raises $185M